Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
TNGX Tango Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: TNGX
Price (delayed)
$3.27
Market cap
$354.45M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.21
Enterprise value
$332.54M
tango therapeutics is a biotechnology company discovering and developing novel medicines targeting cancer vulnerabilities to deliver transformational new therapies for patients. tango was launched in 2017 with a $55 million
Highlights
The debt has contracted by 3.4% YoY
The revenue rose by 10% YoY but it fell by 2.6% QoQ
The gross profit rose by 10% year-on-year but it has declined by 2.6% since the previous quarter
The equity has decreased by 37% YoY and by 16% QoQ
Tango Therapeutics's quick ratio has decreased by 25% YoY and by 11% from the previous quarter
Key stats
What are the main financial stats of TNGX
Market
Valuations
Earnings
Shares outstanding
108.39M
Market cap
$354.45M
Enterprise value
$332.54M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.12
Price to sales (P/S)
8.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.11
Revenue
$40.99M
Gross profit
$40.99M
Operating income
-$145.87M
Net income
-$132.26M
EBIT
-$132.06M
EBITDA
-$125.73M
Free cash flow
-$135.95M
Per share
Balance sheet
Liquidity
EPS
-$1.21
EPS diluted
-$1.21
Free cash flow per share
-$1.23
Book value per share
$1.54
Revenue per share
$0.37
TBVPS
$2.49
Total assets
$274.31M
Total liabilities
$107.55M
Debt
$36.95M
Equity
$166.76M
Working capital
$189.01M
Debt to equity
0.22
Current ratio
6.26
Quick ratio
6.05
Net debt/EBITDA
0.17
Margins
Efficiency
Dividend
EBITDA margin
-306.7%
Gross margin
100%
Net margin
-322.7%
Operating margin
-355.9%
Return on assets
-39.9%
Return on equity
-62.8%
Return on invested capital
-48.7%
Return on capital employed
-55.4%
Return on sales
-322.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TNGX stock price
How has the Tango Therapeutics stock price performed over time
Intraday
0.93%
1 week
68.56%
1 month
116.56%
1 year
-54.07%
YTD
5.83%
QTD
138.69%
Financial performance
How have Tango Therapeutics's revenue and profit performed over time
Revenue
$40.99M
Gross profit
$40.99M
Operating income
-$145.87M
Net income
-$132.26M
Gross margin
100%
Net margin
-322.7%
The company's net income fell by 18% YoY
Tango Therapeutics's operating income has decreased by 16% YoY
The revenue rose by 10% YoY but it fell by 2.6% QoQ
The gross profit rose by 10% year-on-year but it has declined by 2.6% since the previous quarter
Price vs fundamentals
How does TNGX's price correlate with its fundamentals
Growth
What is Tango Therapeutics's growth rate over time
Valuation
What is Tango Therapeutics stock price valuation
P/E
N/A
P/B
2.12
P/S
8.8
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.11
Tango Therapeutics's EPS has decreased by 9% YoY
The stock's P/B is 53% less than its 5-year quarterly average of 4.5 and 16% less than its last 4 quarters average of 2.5
The equity has decreased by 37% YoY and by 16% QoQ
TNGX's price to sales (P/S) is 60% lower than its 5-year quarterly average of 21.6 and 34% lower than its last 4 quarters average of 13.2
The revenue rose by 10% YoY but it fell by 2.6% QoQ
Efficiency
How efficient is Tango Therapeutics business performance
TNGX's ROIC is down by 45% YoY and by 13% from the previous quarter
The ROA is down by 45% year-on-year and by 11% since the previous quarter
The ROE is down by 42% year-on-year and by 13% since the previous quarter
Tango Therapeutics's return on sales has decreased by 8% YoY and by 4.2% QoQ
Dividends
What is TNGX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TNGX.
Financial health
How did Tango Therapeutics financials performed over time
The total assets is 155% more than the total liabilities
The total assets has contracted by 32% YoY and by 13% from the previous quarter
Tango Therapeutics's quick ratio has decreased by 25% YoY and by 11% from the previous quarter
The debt is 78% less than the equity
The debt to equity has surged by 57% year-on-year and by 22% since the previous quarter
The equity has decreased by 37% YoY and by 16% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.